Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • CCC Cancer Update
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Oncogene. 2017 Sep 18. pii: onc2017341. doi: 10.1038/onc.2017.341
    A slow-cycling subpopulation of melanoma cells with highly invasive properties.
    Perego M1,  Maurer M2,  Wang JX3,  Shaffer S4,  Müller AC5,  Parapatics K6,  Li L7,  Hristova D8,  Shin S9,  Keeney F10,  Liu S11,  Xu X12,  Raj A13,  Jensen JK14,  Bennett KL15,  Wagner SN16,  Somasundaram R17,  Herlyn M18
    Author information
    1Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
    2Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria.
    3Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
    4Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
    5CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
    6CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
    7Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
    8Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
    9Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
    10Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
    11Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
    12Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
    13Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
    14Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
    15CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
    16Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria.
    17Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
    18Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
    Abstract

    Melanoma is a heterogeneous tumor with different subpopulations showing different proliferation rates. Slow-cycling cells were previously identified in melanoma, but not fully biologically characterized. Using the label-retention method, we identified a subpopulation of slow-cycling cells, defined as label-retaining cells (LRC), with strong invasive properties. We demonstrate through live imaging that LRC are leaving the primary tumor mass at a very early stage and disseminate to peripheral organs. Through global proteome analyses, we identified the secreted protein SerpinE2/protease nexin-1 as causative for the highly invasive potential of LRC in melanomas.Oncogene advance online publication, 18 September 2017; doi:10.1038/onc.2017.341.


    Publikations ID: 28925403
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt